CLLTAXS01 / ViferaXS - LARVOL DELTA

ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline (PRNewswire) - "The proceeds will fund ViferaXS' lead programme, a Phase II clinical trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), and support ViferaXS' broader pipeline. In parallel, the financing supports ongoing Phase I programmes in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC)."

Financing • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hepatocellular Cancer